Ionizable lipidoids and their uses

Patent metadata

Field	Value
Publication number	US-11459304-B2
Application number	US-201916556470-A
Country	US
Kind code	B2
Filing date	Aug 30, 2019
Priority date	Aug 31, 2018
Publication date	Oct 4, 2022
Grant date	Oct 4, 2022

Abstract

Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.

First claim

What is claimed is:

1. A compound of Formula (I-A):

or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein:
X is NH, O, or S;
R 1 is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R 2 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or nitrogen protecting group; and
each instance of R 3 is independently optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; or wherein two instances of R 3 are taken together with their intervening atoms to form a ring.

2. The compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein X is O.

3. The compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein R 1 is optionally substituted C 1-6 alkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein R 2 is optionally substituted C 1-6 alkyl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein R 1 is optionally substituted C 1-6 alkyl, R 2 is optionally substituted C 1-6 alkyl, and each R 3 independently is optionally substituted C 1-20 alkyl, optionally substituted C 2-20 alkenyl, or optionally substituted C 2-20 alkynyl.

6. The compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein R 2 is of the formula: —(CH 2 ) n N(R D1a ) 2 ,
wherein:
each instance of R D1a is independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, and a nitrogen protecting group; or optionally two instances of R D1a are taken together with their intervening atoms to form a substituted or unsubstituted heterocyclic or substituted or unsubstituted heteroaryl ring; and
n is 1, 2, 3, 4, 5, or 6.

7. The compound of claim 6 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein at least one instance of R D1a is hydrogen, or wherein at least one instance of R D1a is optionally substituted C 1-6 alkyl.

8. The compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, wherein R 2 is of the formula: —(CH 2 ) n OR D1 , and wherein:
R D1 is independently selected from hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or an oxygen protecting group when attached to an oxygen atom; and
n is 1, 2, 3, 4, 5, or 6.

9. The compound of claim 1 , wherein the compound is of the formula:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is synthesized by a method comprising reacting:
an amine of Formula (A):
R 2 —NH 2   (A);

an isocyanide of Formula (B):

and
a ketone of Formula (C):

to form a compound of claim 1 ; wherein:
X is NH, O, or S;
R 1 is hydrogen, optionally substituted acyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
R 2 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or nitrogen protecting group; and
each instance of R 3 is independently optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

11. The compound of claim 10 , or a pharmaceutically acceptable salt thereof, wherein X is O.

12. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt, co-crystal, tautomer, stereoisomer, solvate, hydrate, polymorph, or isotopically enriched derivative thereof, and an agent.

13. The composition of claim 12 , wherein the agent is a small organic molecule, inorganic molecule, nucleic acid, protein, peptide, or polynucleotide.

14. The composition of claim 13 , wherein the agent is a polynucleotide.

15. The composition of claim 14 , wherein the polynucleotide is DNA.

16. The composition of claim 14 , wherein the polynucleotide is RNA.

17. The composition of claim 16 , wherein the RNA is double-stranded RNA (dsRNA), small interfering RNA (siRNA), short hairpin RNA (shRNA), micro RNA (mi RNA), messenger RNA (mRNA), or antisense RNA.

18. The composition of claim 16 , wherein the RNA is mRNA.

19. The composition of claim 18 , wherein the mRNA encodes a protein.

20. The composition of claim 19 , wherein the protein is an antigen.

21. The composition of claim 18 , wherein the mRNA is an mRNA vaccine.

22. The composition of claim 12 , wherein the agent is an anti-cancer agent.

Assignees

• Massachusetts Inst Technology

Inventors

• Miao Lei
• Li Linxian
• Anderson Daniel Griffith
• Huang Yuxuan

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• C07C251/08

  being acyclic · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• C07D233/26 Primary

  Radicals substituted by carbon atoms having three bonds to hetero atoms · CPC title

• C07C237/16

  the carbon skeleton being acyclic and unsaturated · CPC title